Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-06-20
2006-06-20
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S135100, C424S141100, C424S142100, C424S143100, C424S144100, C424S173100, C435S326000, C435S327000, C435S332000, C435S334000, C435S343000, C435S343100, C530S387100, C530S388100, C530S388150, C530S388200, C530S388220, C530S388700, C530S388730, C536S023100, C536S023500, C536S023530
Reexamination Certificate
active
07063845
ABSTRACT:
The invention is directed to human antibodies that bind CD40 (e.g., human CD40), methods of producing the antibodies and methods of use. Invention human CD40 antibodies include antibodies that can modulate one or more activities of CD40, such as increasing or decreasing cell proliferation. Invention human CD40 antibodies are therefore useful for increasing or decreasing a CD40 activity in order to alter CD40 activity in vivo.
REFERENCES:
patent: 5677165 (1997-10-01), de Boer et al.
patent: 5786456 (1998-07-01), Ledbetter et al.
patent: 5801227 (1998-09-01), Fanslow, III et al.
patent: 5874082 (1999-02-01), De Boer
patent: 6004552 (1999-12-01), de Boer et al.
patent: 6051228 (2000-04-01), Aruffo et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 0945 465 (1999-09-01), None
patent: 0972 445 (2000-01-01), None
patent: WO 91/09115 (1991-06-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 99/42075 (1999-08-01), None
patent: WO 99/61051 (1999-12-01), None
patent: WO 00/00156 (2000-01-01), None
patent: WO 00/75348 (2000-12-01), None
patent: WO 00/75348 (2000-12-01), None
patent: WO 01/24823 (2001-04-01), None
patent: WO 01/56603 (2001-08-01), None
patent: WO 01/83755 (2001-11-01), None
patent: WO 01/83755 (2001-11-01), None
patent: WO 02/28904 (2002-04-01), None
patent: WO 02/28904 (2002-04-01), None
Tomizuka, et al., “Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing Ig heavey and kappa loci and expression of fully human antibodies”, PNAS, Jan. 18, 2000, vol. 97, No. 2.
Schoenberger, et al., “T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions”, Nature, vol. 393, Jun. 4, 1998.
Stamenkovic, et al., “A B-lymphocyte activation molecule related to the nerve growth factor receptor and inuced by cytokines in carcinomas”, The EMBO Journal, vol. 8, No. 5, pp. 1403-1410, 1989.
Clark, et al., “CDw40 and BLCa-specific monoclonal antibodies detect two distinct molecules which transmit progression signals to human B lymphocytes*”, Eur. J. Immunol., 1988, 18: 451-457.
Ledbetter, et al., Augmentation of Normal and Malignant B Cell Proliferation by Monoclonal Antibody to the B Cell-Specific Antigen BP50 (CDW40), The Journal of Immunology, vol. 138, pp. 788-794, No. 3, Feb. 1, 1987.
Clark, et al., “Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50”, Proc. Natl. Acad. Sci. USA, vol. 83, pp. 4494-4498, Jun. 1986.
Paulie, et al., “A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes”, Cancer Immunology Immunother, (1985), 20: 23-28.
Kwekkeboom, et al., “Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction,”Eur. J. Immunol, (1994), vol. 24, pp. 508-517.
Hasbold, et al., “Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4,”Eur. J. Immunol. (1998), vol. 28, pp. 1040-1051.
Pound, et al., “Minimal cross-linking and eptiope requirements for D40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotyic adhesions in human B cells,”Int'l Immunol. (1999), vol. 11, No. 1, pp. 11-20.
Francisco, et al., “Agonistic Properties and in vivo Antitumor of the Anti-CD40 Antibody SGN-14,”Cancer Research, (Jun. 15, 2000), vol. 60, pp. 3225-3231.
Roamno, et al., “Triggering of CD40 Antigen Inhibits Fludarabine-Induced Aoptosis in B Chronic Lymphocytic Leukemia Cells,”Blood, (Aug. 1, 1998) vol. 98, No. 3, pp. 990-995.
Hirano, et al., “Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD40 Ligand,”Blood, (May 1, 1999), vol. 93, No. 9, pp. 2999-3007.
Francisco, et al., “Construction, Expression, and Characterization of BD1-G28-5 sFv, a Single-chain Anti-CD40-Immunotoxin Containing the Ribosome—of BD—in activating Protein Bryodin 1,”Journal of Biological Chemistry, (Sep. 26, 1997), vol. 272, No. 39, pp. 24165-24169.
Maxwell, et al., “Contrasting the Roles of Costimulation and the Natural Adjuvant Lipopolysaccharide During the Induction of T Cell Immunity,”J. Immunol., (May 1, 2002), vol. 168, No. 9, pp. 4372-4381.
Simonsson, et al., “Single, Antigen-Specific B Cells Used to Generate Fab Fragments Using CD40-Mediated Amplification or Direct PCR Cloning,”BioTechniques, (1995), vol. 18, No. 5, pp. 862-869.
Duliforce, et al., “Enhancement of T cell-independent immune responses in vivo by CD 40 antibodies,”Nature Medicine, (Jan. 1998), vol. 4, No. 1, pp. 88-91.
Erickson, et al., “Short-circuiting long-lived humoral immunity by the heightened engagement of CD40,”The J. of Clinical Investigation, (Mar., 2002), vol. 109, No. 5, pp. 613-620.
Murphy, et al., “Antibodies to CD40 Prevent Epstein-Barr Virus- Mediated Human B-Cell Lymphomagenesis in Severe Combined Immune Deficient Mice Given Human Peripheral Blood Lymphocytes,”Blood, (Sep. 1, 1995), vol. 86, No. 5, pp. 1946-1953.
Funakoshi, et al., “Differential in vitro and in vivo Antintumor Effects Mediated by Anit-CD40 and Anti-CD20 Monoclonal Antibodies Against Human B-Cell Lyphomas,”J. of Immunology, (1996) vol. 19, No. 2, pp. 93-101.
Schwabe, et al., “Modulation of Soluble CD40 Ligand Bioactivity with Anti-CD40 Antibodies,”Hybridoma, (1997), vol. 16, No. 13, pp. 217-226.
Funakoshi, et al., “Inhibition of Human B-Cell Lymphoma Growth by CD40 Stimulation,”Blood, (May 15, 1994), vol. 83, No. 10, pp. 2787-2794.
Rolink, et al., “The SCID but Not the RAG-2 Gene Product Is Required for Sμ-Sε Heavy Chain Class Switching,”Immunity, (Oct., 1996) vol. 5, pp. 319-330.
Kwekkeboom, et al., “CD40 plays and essential role in the activation of human B cells by murine EL4B5 cells,”Immunology, (1993), vol. 79, pp. 439-444.
Zhou, et al., “An Agonist Anti-Human CD40 Monoclonal Antibody that Induces Dendritic Cell Formation and Maturation and Inhibits Proliferation of a Myeloma Cell Line,”Hybridoma, vol. 18, No. 6, 1999, pp. 471-478.
Heath, et al., “Monoclonal antibodies to murine CD40 define two distinct functional epitopes,”Eur. J. Immunology, (1994) vol. 24, pp. 1828-1834.
Mazzei, et al., “Recombinant Soluble Trimeric CD40 Ligand Is Biologically Active,”Journal of Biological Chemistry, (Mar. 31, 1995), vol. 270, No. 13, pp. 7025-7028.
Hasbold, et al., “Properties of mouse CD40: cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies,”Eur. J. Immunology., (1994) vol. 24, pp. 1835-1842.
Weng, et al., “Human Anti-CD40 Antagonistic Antibodies Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma,” Program of the 43rdAnnual Meeting of The American Society of Hematology, (Dec. 7-11, 2001), Abstract No. 1947, p. 466a.
Ledbetter, et al., “Agonistic Activity of a CD40-Specific Single-Chain Fv Constructed from the Variable Regions of mAb G28-5,”Critical Reviews in Immunology, (1997), vol. 17, pp. 427-435.
de Boer, et al., “Generation of monoclonal antibodies to human lymphocyte cell surface antigens using insect cells expressing recombinant proteins,”Journal of Immunological Methods, (1992) vol. 152, pp. 15-23.
Karlsson, et al., “Selection of human single chain antibodies against CD-40,”Immunology Letters, vol. 73, Nos. 2,3, Abstract No. 358.
Sotomayor, et al., “Conversion of tumor-specific CD4 T-cell tolerance to T-cell priming through in vivo ligation of CD40,”Nature, (Jul., 1999), vol. 5, No. 7, pp. 780-787.
Diehl, et al., “CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and
Chen Xingjie
Mikayama Toshifumi
Schoenberger Stephen P.
Takahashi Nobuaki
Gambel Phillip
Gemini Science, Inc.
La Jolla Institute for Allergy & Immunology
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
Human anti-CD40 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human anti-CD40 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human anti-CD40 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3632388